Literature DB >> 24567619

Case-finding for hepatitis C in primary care: a mixed-methods service evaluation.

Shivani Datta1, Jeremy Horwood, Matthew Hickman, Debbie Sharp.   

Abstract

BACKGROUND: Hepatitis C is often asymptomatic, presenting with liver failure and cancer decades after infection. People who inject drugs (PWID) and immigrant populations from countries with a moderate-to-high prevalence of hepatitis C virus (HCV) are the main risk groups. Deaths and hospital admissions due to HCV cirrhosis tripled between 1998 and 2010, but the majority of people with chronic HCV are unaware of it. AIM: To identify patients at risk of developing hepatitis C using routine GP data, to determine the proportion not tested, and to explore GPs' views regarding testing. DESIGN AND
SETTING: Mixed-methods service evaluation (density-based selection of PWID) in six NHS practices in Bristol.
METHOD: Patients at risk of HCV were identified. The Health Protection Agency laboratory (now part of Public Health England) provided test results. Semi-structured interviews with 17 GPs were audiorecorded and thematic analyses conducted on anonymised transcripts.
RESULTS: Of 3765 patients identified as being at risk of developing hepatitis C, 3051 (81%) had no test result, including 53% of PWID and 93% of the 'ethnicity' group. All GPs said they usually test PWID. Most GPs test for HIV and hepatitis B in immigrants more often than they test for HCV. Barriers to testing included not questioning patients about risk factors, competing priorities, the chaotic lifestyle of PWID, difficulty extracting information from computerised records, and forgetting to address HCV.
CONCLUSION: Computer prompts and GP education on whom to test are warranted. Ensuring that country of origin and drug use is included on the new-patient questionnaire might also aid case-finding for HCV.

Entities:  

Keywords:  evaluation research; hepatitis C; primary health care; screening

Mesh:

Year:  2014        PMID: 24567619      PMCID: PMC3905404          DOI: 10.3399/bjgp14X677112

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  29 in total

1.  Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators.

Authors:  Matthew Hickman; Vanessa Higgins; Vivian Hope; Mark Bellis; Kate Tilling; Angeline Walker; John Henry
Journal:  J Epidemiol Community Health       Date:  2004-09       Impact factor: 3.710

2.  An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales.

Authors:  D De Angelis; M Sweeting; Ae Ades; M Hickman; V Hope; M Ramsay
Journal:  Stat Methods Med Res       Date:  2008-11-26       Impact factor: 3.021

3.  Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action.

Authors:  Mathew Hickman; Vivian Hope; Barbara Coleman; John Parry; Maggie Telfer; John Twigger; Charles Irish; John Macleod; Hugh Annett
Journal:  J Public Health (Oxf)       Date:  2009-07-11       Impact factor: 2.341

4.  Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study.

Authors:  Charlotte Ne Tompkins; Nat Mj Wright; Lesley Jones
Journal:  Br J Gen Pract       Date:  2005-04       Impact factor: 5.386

Review 5.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

6.  Context of clinical care: the case of hepatitis C in underserved communities--a report from the Primary Care Multiethnic Network (PRIME Net) Consortium.

Authors:  Robert R Leverence; Robert L Williams; Wilson Pace; Bennett Parnes; Yvonne Fry-Johnson; Dorothy R Pathak; Betty Skipper; Elvan Daniels; Philip Kroth
Journal:  J Am Board Fam Med       Date:  2009 Nov-Dec       Impact factor: 2.657

7.  Hepatitis C infection among drug users attending general practice.

Authors:  W Cullen; G Bury; J Barry; F D O'Kelly
Journal:  Ir J Med Sci       Date:  2003 Jul-Sep       Impact factor: 1.568

8.  A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.

Authors:  Arthur Y Kim; Ellen H Nagami; Christopher E Birch; Melinda J Bowen; Georg M Lauer; Barbara H McGovern
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

9.  Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort.

Authors:  David T Arnold; Louise M Bentham; Ruth P Jacob; Richard J Lilford; Alan J Girling
Journal:  BMC Fam Pract       Date:  2011-03-03       Impact factor: 2.497

Review 10.  The ongoing impacts of hepatitis c--a systematic narrative review of the literature.

Authors:  Emma R Miller; Stephen McNally; Jack Wallace; Marisa Schlichthorst
Journal:  BMC Public Health       Date:  2012-08-18       Impact factor: 3.295

View more
  4 in total

1.  Barriers to and facilitators of hepatitis C virus screening and testing: A scoping review.

Authors:  N Shehata; T Austin; S Ha; K Timmerman
Journal:  Can Commun Dis Rep       Date:  2018-07-05

2.  'Just another vial…': a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK.

Authors:  Lucy Cullen; Pippa Grenfell; Alison Rodger; Chloe Orkin; Sema Mandal; Tim Rhodes
Journal:  BMJ Open       Date:  2019-05-01       Impact factor: 2.692

3.  Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.

Authors:  Lauren M K Mason; Irene K Veldhuijzen; Erika Duffell; Ayla van Ahee; Eveline M Bunge; Andrew J Amato-Gauci; Lara Tavoschi
Journal:  J Viral Hepat       Date:  2019-08-16       Impact factor: 3.728

4.  Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial.

Authors:  Jeremy Horwood; Clare Clement; Kirsty Roberts; Cherry-Ann Waldron; William L Irving; John Macleod; Mathew Hickman
Journal:  Br J Gen Pract       Date:  2020-07-30       Impact factor: 5.386

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.